Filing Flows › Karyopharm Therapeutics (KPTI) › Q2 2026 › vs Q2 2025
Karyopharm Therapeutics (KPTI) Q2 2026 vs Q2 2025 (year over year)
Karyopharm Therapeutics's revenue fell $4.5M (-12%) from $37.9M in Q2 2025 to $33.4M in Q2 2026. The biggest changes: License and Other −$5.6M (-68%); Product +$1.1M (+4%).
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $30.8M | $29.7M | $1.1M | +4% |
| License and Other | $2.7M | $8.2M | −$5.6M | -68% |
| Revenue | $33.4M | $37.9M | −$4.5M | -12% |
| Net loss | $67.0M | $37.3M | $29.8M | +80% |
| Costs & expenses | $100M | $75.2M | $25.3M | +34% |
| Operating costs | $56.0M | $62.3M | −$6.4M | -10% |
| Interest & other, net | $44.5M | $12.8M | $31.7M | +247% |
| Research & development | $29.0M | $32.8M | −$3.8M | -12% |
| SG&A | $25.9M | $28.5M | −$2.6M | -9% |
| Other operating costs | $1.1M | $1.1M | $34K | +3% |
| Operating cash sources | $67.0M | $37.2M | $29.8M | +80% |
| Share-based compensation | $1.9M | $3.8M | −$1.9M | -49% |
| Working capital & other | $40.2M | $14.7M | $25.5M | +173% |
| Cash used in operations | $24.9M | $18.7M | $6.2M | +33% |
| Net loss absorbed | $67.0M | $37.3M | $29.8M | +80% |
Questions
How much did Karyopharm Therapeutics's revenue grow year over year in Q2 2026?
Karyopharm Therapeutics's revenue fell $4.5M (-12%) from $37.9M in Q2 2025 to $33.4M in Q2 2026.
What drove Karyopharm Therapeutics's revenue change in Q2 2026?
License and Other −$5.6M (-68%); Product +$1.1M (+4%).